Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).
Truong H DoMadeleine A HowardElise F PalzerJared D HulingMohammed A AlviSamuel W CramerPing ZhuReid A JohnsonJames JeanJinci LuAlec B JonasonJacob HansonLuke SabalKevin W SunRobert A McGovernClark C ChenPublished in: Journal of neuro-oncology (2022)
The likelihood of 30- and 90-day readmission for malignant brain tumor patients who underwent LITT or SNB are comparable, supporting the safety profile of LITT as therapy for malignant brain cancers.
Keyphrases
- patients undergoing
- end stage renal disease
- ultrasound guided
- ejection fraction
- newly diagnosed
- prognostic factors
- quality improvement
- mesenchymal stem cells
- multiple sclerosis
- resting state
- patient reported outcomes
- blood brain barrier
- mass spectrometry
- brain injury
- brain metastases
- adverse drug
- electronic health record